A Post-Market Randomized Controlled Trial to Evaluate the Efficacy of VELVERT Antimicrobial Wound Dressing Versus Framycetin Cream in Infected Wounds

Background:  The primary objective of this comparative study was to assess the efficacy of a new antimicrobial wound dressing (VELVERT) against infected wound in comparison to standard of care (Framycetin cream). Velvert is a breathable, non-adherent, and topical wound dressing.

Methods: Patients with infected wound were assessed and divided to receive Velvert or standard of care treatment. Wound assessment was carried out using BWAT score and bacterial load assessment. The clinician’s opinion of the dressing’s performance was surveyed through assessment of surgeon’s questionnaire. Pain levels was evaluated using a 0-10 Numeric Pain Chart.

Results: On day 24, the VELVERT dressing group exhibited 58.16% (± 30.15) reduction in wound size whereas, in the standard of care group 55.76 % (± 23.61) reduction was observed. BWAT scores have generally improved (showing lower scores) wound healing. VELVERT was found to be effective in reducing the severity and prevalence of various microorganisms. The assessment of Surgeon's Questionnaire results showed a positive user experience.

Conclusion: The dressing was well-received by patients and resulted in positive clinician experience. VELVERT showed the potential to offer advancements in wound care for patients with infected wounds. This is a promising novel dressing that could offer significant advantages to improve the quality, and convenience of wound care.